Clesacostat/Ervogastat

N/A

Report date: 2025/12/18 16:42:11

Base Information

Drug NameClesacostat/Ervogastat
Drug Alias NamePF-05221304/PF-06865571PF-07055341
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDiacylglycerol O-acyltransferase 1 inhibitorsDiacylglycerol O-acyltransferase 2 inhibitorsAcetyl-CoA carboxylase inhibitors
TargetsDiacylglycerol O-acyltransferase 1Diacylglycerol O-acyltransferase 2Acetyl-CoA carboxylase
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes ClesacostatErvogastat
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A